Last reviewed · How we verify
LY3473329
At a glance
| Generic name | LY3473329 |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) (PHASE3)
- A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events (PHASE2)
- A Study of LY3473329 in Participants With Impaired and Normal Renal Function (PHASE1)
- A Study of Carbon-14-Labelled [14C] LY3473329 in Healthy Male Participants (PHASE1)
- A Study of LY3473329 in Healthy Japanese Participants (PHASE1)
- A Study of LY3473329 in Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3473329 CI brief — competitive landscape report
- LY3473329 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI